Cue Biopharma, Inc. (CUE) Stock Price & Analysis
Cue Biopharma, Inc. (CUE) fell 2.93% to USD 32.12 as of July 25, 2026 at 10:02 UTC, according to Nexqual real-time market data.
CUE last closed at USD 33.09; the session ranged USD 31.15–33.52 on volume of 147,112 shares. Market capitalization is $134.92M, with a 52-week range of USD 4.98–45.5 (NCM). Source: Nexqual, July 25, 2026 at 10:02 UTC.
Key Statistics (as of July 25, 2026 at 10:02 UTC)
| Price | USD 32.12 |
|---|---|
| Change | ▼ 2.93% (down) |
| Previous Close | USD 33.09 |
| Open | USD 32.79 |
| Day Range | USD 31.15 – 33.52 |
| 52-Week Range | USD 4.98 – 45.5 |
| Volume | 147,112 shares |
| Market Cap | $134.92M |
| Exchange | NCM |
Technical Analysis (CUE)
Nexqual's technical model rates CUE "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 10:02 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 51.73 (neutral) |
| vs SMA50 | Above (USD 27.8) |
| MACD | 1.33 (positive) |
Analyst Ratings (CUE)
Wall Street analysts rate CUE "None" based on 1 analysts, with a mean price target of USD 115 (range USD 115–115), per Nexqual as of July 25, 2026 at 10:02 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 115 |
| High Target | USD 115 |
| Low Target | USD 115 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (CUE)
| Revenue Estimate | $3.00M |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD 0.3 vs est -2.7 ▲ beat |
| 2025-09-30 | USD -2.1 vs est -2.55 ▲ beat |
| 2025-06-30 | USD -2.7 vs est -3.9 ▲ beat |
Source: Nexqual, July 25, 2026 at 10:02 UTC.
Financials & Fundamentals (CUE)
| Total Revenue | $32.73M |
|---|---|
| Revenue Growth (YoY) | +1250.60% |
| Gross Margin | -2.63% |
| Operating Margin | -94.32% |
| Profit Margin | -59.65% |
| ROE | -138.52% |
| Debt / Equity | 15.92 |
| Current Ratio | 3.57 |
| Total Cash | $17.44M |
| Total Debt | $3.44M |
| Free Cash Flow | $-14.90M |
Source: Nexqual, July 25, 2026 at 10:02 UTC.
Financial Health Score (CUE)
Nexqual rates Cue Biopharma, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 10:02 UTC.
| Growth | Strong — Revenue +196% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $17M cash vs $3M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$15M, burning cash |
| Efficiency | Critical — ROE -139%, ROA -46.1% |
Ownership (CUE)
| Insider Ownership | +17.96% |
|---|---|
| Institutional Ownership | +13.89% |
| Shares Outstanding | 4.20M |
| Float | 3.66M |
| Short % of Float | +7.99% |
Source: Nexqual, July 25, 2026 at 10:02 UTC.
Leadership (CUE)
Cue Biopharma, Inc. is led by Shao-Lee Lin (age 58), President, CEO & Director, per Nexqual as of July 25, 2026 at 10:02 UTC.
| President, CEO & Director | Shao-Lee Lin (age 58) |
|---|---|
| Principal Fin & Accounting Off. and Chief Financial & Business Officer | Lucinda Warren (age 56) |
| Senior Vice President of Intellectual Property | Colin G. Sandercock J.D., MSE (age 68) |
| Co-Founder and Chairman of Scientific & Clinical Advisory Board | Steven C. Almo (age 64) |
Major Backers & Investors (CUE)
Notable institutional backers of Cue Biopharma, Inc. include Bleichroeder LP, Lion Point Capital, LP, Fidelity, according to Nexqual as of July 25, 2026 at 10:02 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bleichroeder LP | 5.41% |
| Lion Point Capital, LP | 1.75% |
| Fidelity | 0.65% |
| Robertson Stephens Wealth Management, LLC | 0.38% |
| Texas Capital Bank Wealth Management Services, Inc. | 0.32% |
| Angeles Wealth Management, LLC | 0.25% |
| Advisory Research, Inc. | 0.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.33% |
| Geode Capital | 0.84% |
| BlackRock | 0.36% |
Source: Nexqual, July 25, 2026 at 10:02 UTC.
From Cue Biopharma, Inc.'s Latest SEC 10-K Filing (filed 2026-03-16)
Key Strengths & Strategy (as disclosed to the SEC)
- CUE-100 Series Historically, we primarily focused our resources on the development of our CUE-100 series for oncology, namely the CUE-101 and CUE-102 drug product candidates, which are representative of our approach to selectively activate targeted CD8+ T cells against cancer, both of which have been licensed to ImmunoScape Pte.
- Plan of Operation Our approach to developing precision immunotherapies has yielded a growing portfolio of novel proteins with the potential to address multiple unmet needs across autoimmune diseases.
- The percentage of such proceeds that we are required to pay Einstein ranges from the low to mid-teens, depending on how far we have developed a Licensed Product before we enter into an agreement relating to the Licensed Product.
- We believe that our approach provides us with a superior competitive advantage and differentiation, with a potentially first-in-class, masked TGF-b and IL-2 designed to address the underlying mechanism of disease by rebalancing the Treg and effector cell ratio . 9   Many of our competitors have greater financial, technical and human resources than we do.
Partnerships
- Under our Collaboration and License Agreement with IMSCP, IMSCP is developing a novel Seed-and-Boost immunotherapy that combines our clinically validated Immuno-STAT T-cell engagers, the CUE-100 series, with IMSCP's proprietary tumor-specific T cell receptors, or TCRs.
- Our Collaboration Agreement with LG Chem On November 6, 2018, we entered into a Collaboration, License and Option Agreement, as amended from time to time, or the LG Chem Collaboration Agreement, with LG Chem Ltd., or LG Chem, pertaining to the development of CUE-101 and CUE-102 Immuno-STATs in Australia and in certain countries in Asia, or the LG Chem Territory.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VRCA | Verrica Pharmaceuticals Inc. | USD 5.02 | ▼ 11.93% |
| STRO | Sutro Biopharma, Inc. | USD 22.88 | ▼ 2.22% |
| CTMX | CytomX Therapeutics, Inc. | USD 3.24 | ▼ 2.7% |
| FULC | Fulcrum Therapeutics, Inc. | USD 3.72 | ▲ 0.54% |
| MGTX | MeiraGTx Holdings plc | USD 11.77 | ▼ 3.21% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:02 UTC. This page is informational and not investment advice.